Ponezumab is a humanized antiamyloid beta (Ab) monoclonal antibody designed to treat Alzheimer disease (AD).
(PMID: 23334070) Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Ab) monoclonal antibody designed for treatment of Alzheimer disease (AD).
(PMID: 23334069) Solanezumab is a humanized anti-amyloid b monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD).
Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.
(PMID: 22134132) LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.
(PMID: 20375655) The most developmentally advanced monoclonal antibody directly targeting Abeta is bapineuzumab, now being studied in a large Phase III clinical trial.
(PMID: 20154508) The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial.
(PMID: 20505438).
